Anatara Lifesciences Limited announced that Mr. John Michailidis has now joined the Anatara team as Chief Operations Officer (COO). As part of the handover, the company have recently met with key opinion leaders in the gastrointestinal field. There remains a pleasing level of interest in both the current trials and potential future trials in paediatric participants and other gastrointestinal diseases and disorders.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.048 AUD | +4.35% | +23.08% | +118.18% |
Apr. 09 | Anatara Lifesciences Begins Recruitment for Irritable Bowel Syndrome Stage Two Trial | MT |
Feb. 28 | Anatara Lifesciences Ltd Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
+118.18% | 5.26M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- ANR Stock
- News Anatara Lifesciences Ltd
- Anatara Lifesciences Limited Appoints John Michailidis as Chief Operations Officer